RxDoctor Payments Data

Melissa Bresnahan, APRN

Internal Medicine · Middleboro, MANPI 1831658061

Payments from drug & device makers

$852in general payments, 2019–2025

Across 11 payments — averaging $77.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$414
  • Novo Nordisk$143
  • Inspire Medical Systems, Inc.$113
  • Bayer$93
  • Phathom Pharmaceuticals, Inc.$50
  • Johnson & Johnson$25
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$852 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$72,367
Medicare patients
229
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$69,985
EliquisApixaban46$44,792
MounjaroTirzepatide40$41,134
JardianceEmpagliflozin21$28,863
TrulicityDulaglutide12$11,141
Fenofibrate13$6,197
XanaxAlprazolam17$6,029
Spiriva RespimatTiotropium Bromide11$5,798
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,256
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,139
Atorvastatin Calcium218$2,995
Advair DiskusFluticasone Propion/Salmeterol14$2,446
Gabapentin135$2,332
Albuterol Sulfate HfaAlbuterol Sulfate77$1,763
Solifenacin Succinate12$1,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$143$69,98558 claims
Lilly USA, LLCMounjaro, Trulicity$14$52,27552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Middleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →